reason report
nmo data make strong case soliri despit competit
bottom line increment encourag phase
prevent data soliri neuromyel optica nmo report
yesterday believ result offer previous underappreci
revenu potenti option alexion medacorp kol
confer call yesterday confirm remark initi report
efficaci soliri also reinforc competit risk off-label
use rituxan appear activ less effect soliri
nmo incorpor updat forecast global sale soliris/
nmo grow rais revenu
forecast franchis
increas price target
reiter outperform rate base previou deep-div
potenti soliri nmo link believ opportun nmo
larg increment investor expect analyst
estim despit guard optim trial potenti
also exclud forecast valuat efficaci
safeti result announc yesterday suggest soliri highli effect
control relaps nmo patient activ diseas despit use
current standard care immunosuppress therapi believ
yesterday stock reaction reflect part valu
could anoth import synergist indic alexion flagship
strong efficaci safeti result de-risk soliri nmo trial
result announc yesterday soliri demonstr reduct risk
relaps compar placebo hr base time
first adjud on-trial relaps exhibit annual relapse-
free rate soliri placebo respect
rel reduct risk adjud
relaps impress efficaci occur despit fact
patient concomit background immunosuppress therapi
ist would boost respons rate control arm
compar histor observ soliri also gener well
toler studi case meningococc infect observ
multi-year studi period
high cost treatment burden could limit soliri use late
line therapi despit fact efficaci soliri appear
superior off-label rituxan medacorp consult suggest
rituxan gener quit effect control diseas
major nmo patient treatment burden modest
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
compani inform leerink partner llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
mainten infus alexion face high hurdl
compet earli line use given higher cost rituxan
greater treatment burden infus year howev
lack treatment option rituxan failur believ still
signific market opportun soliri late line treatment nmo
peak global sale soliri nmo includ model pt
built forecast revenu potenti soliri
indic base patient anti-aquaporin
antibodi fail achiev adequ
respons rituxan popul forecast peak penetr
us row soliri global sale forecast
soliri nmo grow
updat industri multipl
revis revenu ep forecast price target
increas reiter outperform rate
stock result studi present later year
earli pay close attent comparison
soliri efficaci placebo patient concomit rituxan
price target rate stock
outperform alexion lead independ compani develop commerci
treatment ultra-rar disord complement system nineti percent revenu today
come soliri approv three differ rare diseas indic
believ alexion increas current revenu run rate complement franchis
competit threat soliri overst view given long safeti
efficaci histori soliri well alexion progress develop improv version
product greater potenc longer half-lif conveni dose beyond soliri alexion
still earli phase launch two addit rare diseas medicin kanuma
strensiq expect contribut approxim combin revenu
alexion maintain reason financi disciplin expect oper margin
bounc back better drop acquisit
synageva cost two product launch alexion remain
one fastest grow busi biopharmaceut durabl larg molecul
protein therapi believ recov multipl come quarter fail
trade discount reason cautiou outlook could becom one target
expect increasingli consolid industri
prevent studi test soliri nmo
prevent phase studi enrol patient diagnosi nmo neuromyel
optic spectrum disord nmosd seroposit nmo-igg random
soliri placebo arm elig patient need experienc
least relaps last month relaps last month least relaps
month prior screen
treatment schedul soliri intraven everi week induct phase
week soliri everi week dose schedul compar
dose regimen atyp hemolyt urem syndrom ahu gener myasthenia
gravi gmg higher paroxysm nocturn hemoglobinuria pnh
weekli first week follow suggest price indic could
also rang per year similar ahu price alon like limit
drug use sever steroid immunosuppress refractori patient nmo
primari endpoint studi time first on-trial relaps adjud
relaps rate disabl qualiti life measur
soliri reduc relaps risk nmo
primari endpoint soliri demonstr reduct risk relaps compar
placebo hr base time first adjud on-trial relaps exhibit
secondari endpoint annual relaps rate reduct soliri
arm rel placebo patient treat soliri placebo
respect free relaps week exhibit separ investigator-
assess outcom on-trial relapse-fre rate week soliri
placebo hazard ration risk reduct reduct
annual relaps rate differ two secondari endpoint
disabl quality-of-lif reach statist signific although come
surpris major impact disabl quality-of-lif happen relaps
patient placebo arm allow cross soliri first adjud
relaps differ two arm two measur would primarili limit
impact first relaps proport relaps patient placebo arm
soliri arm relaps patient
exhibit time first adjud on-trial nmo relaps
exhibit central adjud investigator-assess nmo relaps
soliri toler meningococc infect prevent studi
soliri gener well toler prevent studi rate advers event
seriou advers event sae lower placebo exposure-adjust basi
treatment discontinu due sae soliri arm placebo arm exhibit
particular interest meningococc infect observ either arm compar
rate meningococc infect pnh trial ahu trial presenc
activ meningococc vaccin absenc meningococc infect studi
could happen chanc also possibl risk meningococc infect get
better manag latest clinic practic medacorp neurologist talk point
increas upper respiratori tract infect could safeti signal reduct
nausea urinari tract infect could potenti explain treatment effect
manifest nmo
exhibit safeti summari prevent studi
take-away puls call soliri result impress dose
disadvantag rituximab
accord medacorp neurologist puls call yesterday current
approv drug nmo drug typic use clinic order lowest
highest efficaci also lowest highest cost includ imuran azathioprin cellcept
mycophenol mofetil rituxan rituximab azathioprin avail low cost gener
although cellcept rituxan costli cost fraction price
year suppli soliri consult estim half patient respond well
azathioprin year patient cellcept well patient
receiv rituxan experi excel diseas control nmo patient estim
adequ control therapi
brief review publish result rituxan nmo patient appear
reduct expand disabl statu scale edss score annual relaps rate
rituxan gener report soliri report rituxan come
singl arm investig sponsor trial well control random trial
relapse-fre rate rituxan although impress still soliri result prevent
studi exhibit medacorp kol reason major patient
prevent studi like immunosuppress non-respond may even includ
patient fail prior rituxan know patient trial treat
form immunosuppress therapi steroid alon
impress efficaci soliri trial make strong case use least late line
therapi nmo although may compet well rituxan earli line
much higher cost greater treatment burden
exhibit efficaci comparison soliri rituxan
given major patient diseas well control one current use
drug notabl rituxan soliri disadvantag term cost dose regimen
despit increment stronger efficaci although dose regimen standard
across publish investigator-sponsor studi rituxan nmo typic treatment
schedul recommend neuromyel optica studi group nemo european
feder neurolog societi efn weekli induct week
follow two infus separ interv everi month
mainten first-year cost rituxan us schedul would
wac basi hand first-year cost soliri schedul
prevent studi would annual cost rituxan follow year
would soliri exhibit dose schedul soliri
infus everi week consid insignific treatment burden kol
puls call rituxan requir infus year mainten treatment vs
infus soliri question whether patient would prefer go infus center
everi week rituxan work reason well major patient
exhibit dose cost comparison soliri rituxan
asid physician patient prefer consult suggest payer alreadi
play import role shape treatment paradigm indic accord
medacorp kol payer activ manag nmo drug demand step
therapi azathioprin mycophenolyt approv use rituxan regardless fact
none drug formal approv nmo interestingli kol expect payer
quickli revers attitud prefer rituxan expens drug soliri
approv indic cover soliri rituxan failur howev given
preced ms drug manufactur provid financi support practic refund
unreimburs amount lessen risk buy-and-bil model kol still believ
payment model could establish nmo drug cost much soliri super-
refractori treatment-resist patient diseas
mani competitor expect also uncertain timelin
coupl compani current drug candid late stage develop nmo
notabl satralizumab roche/chugai inebilizumab exhibit
trial recruit slowli possibl mani patient well manag rituxan
patient incent join clinic trial also unclear project
data readout timelin met product given alexion delay expect
readout sever time past year total although rituxan use off-label
nmo appear roch advanc medicin formal approv
exhibit compet nmo drug develop
activ cannabinoid
receptor
revenu potenti seemingli larg base preval like limit
preval estim nmo variabl mani sourc kol discuss
indic popul size approxim size multipl sclerosi
preval equat roughli us patient although estim base olmstead
counti data predict potenti much higher preval rang flanagan
et al ann neurol preval appear driven ethnic
race aspect confirm medacorp kol discuss therefor estim
similar preval per person europ major rest world rowjapan
canada latin america soliri avail estim equat approxim
patient europ patient row
roughli nmo patient approxim biomark
elig treatment papadopoulo lancet neurol also believ
avail evid efficaci rel lower price rituxan mean almost patient
step-through rituxan get soliri therefor applic popul like
patient would relaps rituxan within month follow-up estim
base literatur yang et al journal neurolog scienc
result estim true popul patient elig soliri amount roughli
exhibit nmo patient elig soliri rituxan relaps
us patient address
eu patient address
soliri
prevail soliri price per year believ penetr highest
us market lower rel basi eu row specif estim
peak penetr could reach patient relaps rituxan us peak
penetr eu row assumpt estim risk-unadjust
sale second year launch grow
sale geograph basi us revenu repres
peak total revenu exhibit
updat leerink market compani model valuat
base updat revenu forecast soliri nmo increas soliri revenu
forecast minim new revenu forecast alexion
larg unchang higher previou forecast
recent consensu consensu non-
gaap ep forecast recent consensu except
forecast line consensu updat industri multipl revis revenu
ep forecast price target increas reiter
outperform rate stock
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use
termin growth rate post give current valu averag three
valuat methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica myasthenia
gravi novel rare diseas medicin time horizon forecast
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
result pivot ahu
result pivot phase
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
leerink alexion select balanc sheet cash-flow item
million
total liabil sharehold equiti
chang asset liabil
purchas issuanc treasuri stock
chang capit stock net
net chang cash/equival
begin period
end period
chang work capit
oper
leerink partner research compani file
analysi stock price leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
leerink estimate earn
current averag larg cap biopharma multipl ep
leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biopharma co celg
impli ep multipl discount vs full multipl
averag method
leerink partner research compani file factset
